Introduction
============

American Heart Association (AHA) and European Resuscitation Council (ERC) Guidelines 2015 for cardiopulmonary resuscitation (CPR) specify that chest compressions should be delivered with a depth of at least 5 cm but not greater than 6 cm at a rate of 100--120/min.[@ehx318-B1]^,^[@ehx318-B2] These specifications are rarely met: compression depth with manual CPR is frequently too shallow, rates are too high, and prolonged interruptions are frequent.[@ehx318-B3]^,^[@ehx318-B4] Mechanical chest compression devices are designed to perform chest compressions at specified rate and depth and therefore were expected to improve outcome. There are at present two widely used and Food and Drug Administration-approved devices: the AutoPulse (Zoll Medical Corporation, Chelmsford, MA, USA), a load-distributed band device that rhythmically compresses and restricts the chest wall and the LUCAS (Physio-Control/Jolife AB, Lund, Sweden), a piston device with a cup that is placed in the centre of the chest and pushes the sternum down over a distance of 5.2 cm and pulls back to the neutral position. Significant improvement of aortic blood pressure and coronary perfusion pressure is documented in humans from the AutoPulse compared with manual chest compressions.[@ehx318-B5] Chest compression with LUCAS resulted in significantly higher end-tidal carbon dioxide in humans compared with manual chest compressions.[@ehx318-B6] For several years, only one randomized clinical trial with the AutoPulse was available (ASPIRE), which was terminated after interim analysis because of a trend to reduced survival to discharge compared with manual control CPR.[@ehx318-B7] None of the more recent randomized clinical trials demonstrated survival benefit of AutoPulse or LUCAS over manual controls.[@ehx318-B8] Anecdotal and possibly biased observations in our hospital and a published letter suggested increased damage caused by mechanical chest compression devices.[@ehx318-B11]

Because of the perceived damage caused by mechanical chest compression devices, we performed a randomized and controlled study with the AutoPulse and the LUCAS in a non-inferiority design. The objective of our study was to investigate the hypothesis that mechanical chest compression devices do not cause an excess of severe or lethal visceral damage compared with manual chest compressions.

Methods
=======

Setting and study design
------------------------

We performed a prospective randomized clinical trial in the setting of a university hospital to study the safety of mechanical chest compression devices AutoPulse and LUCAS during CPR. The study was approved by the Medical Ethics Committee of our hospital with deferred consent because of the emergency situation, including the use of data from patients who did not survive out-of-hospital cardiac arrest (OHCA). Survivors of the arrest were approached for written consent, and patients refusing consent were withdrawn from the analysis. Clinical trial registration: ISRCTN14647429 (LUCAS) and ISRCTN75393297 (AutoPulse).

Patients
--------

Patients were included between 3 November 2008 and 26 May 2014. Included were patients either with an in-hospital cardiac arrest (IHCA) or with an OHCA after arrival at the emergency department with ongoing CPR. All patients had a shorter (IHCA) or longer (OHCA) period of manual CPR before inclusion in the study. Excluded were patients with a traumatic cause of the arrest, patients with known or estimated age \<18 years, patients who arrived at the emergency room with a mechanical chest compression device already applied by the ambulance crew, patients who had return of spontaneous circulation before application of the study device, and patients who had no cardiac arrest.

Randomization and masking
-------------------------

Randomization was done by computer-generated random numbers. Initially, we randomized patients to be treated either by a LUCAS chest compression device or control (LUCAS study) or by an AutoPulse chest compression device or control (AutoPulse study). Per-patient randomization with 1:1 allocation to either LUCAS study or AutoPulse study study was followed by per-patient randomization with 1:1 allocation to the study device or to manual control CPR, and the resulting treatment allocation concealed in opaque envelopes that were placed at the coronary care unit (CCU). Patients randomized to control treatment received manual chest compressions with corrective feedback of compression depth and rate from the sternal displacement transducer of a Philips Heartstart MRx defibrillator (Philips Healthcare, Eindhoven, The Netherlands). After randomization of 69 patients and observing a lower-than-expected inclusion rate, we decided to merge the patients allocated to the two control groups up to that moment into one control group for use in both comparisons and changed the allocation to 1:1:1 for AutoPulse:LUCAS:control for the remainder of the study (*Figure [1](#ehx318-F1){ref-type="fig"}*). The control patients in both comparisons therefore included the same patients. This change in randomized treatment allocation was made before any blinded outcome assessment had been done. The data and safety monitoring committee approved this change in the protocol.

![Flowchart displaying randomization, exclusion, and inclusion. CC, chest compression; ROSC, return of spontaneous circulation; CT, computed tomography.](ehx318f1){#ehx318-F1}

Procedures
----------

One AutoPulse device, one LUCAS device, and one Philips MRx defibrillator were stationed at the CCU, together with the randomization envelopes. The devices were operated by the CCU nurses who participated in the regular hospital resuscitation team. All CCU nurses received training courses from the manufacturers of the compression devices in their correct and rapid application and handling and received refresher courses every 6 months. When an alert for a possible cardiac arrest was received at the CCU, one sealed randomization envelope was opened. The hospital resuscitation team then took the corresponding device to the site of the arrest, being the location of the in-hospital arrest or the emergency department where the patient arrived after OHCA with ongoing CPR. After arrival on-site, the resuscitation team confirmed that CPR was still ongoing, then evaluated the patients for possible exclusion criteria. If none of the exclusion criteria applied, the patients were treated with the designated device. Final inclusion and exclusion decisions therefore were done after randomization had taken place and was not blinded to the allocated treatment. If the mechanical chest compression device did not operate as intended because of battery failure or other malfuction, the device was removed from the patient, manual chest compression administered, and the patient was excluded from analysis.

Chest compression data from all patients were obtained from a LifePak 12 defibrillator (Physio-Control, Redmond, WA, USA) and analysed with specific software (CodeStat Suite V9, Physio-Control, Redmond, WA, USA) with automated time synchronization. The moment of initiation and termination of AutoPulse or LUCAS compressions was identified by the characteristic pattern of the impedance signal. From patients randomized to manual chest compressions, compression duration, rate, and depth were analysed with Q-CPR review software V 2.1 (Laerdal Medical, Stavanger, Norway). For patients with an OHCA, the duration of chest compressions before connection of the study device was estimated from the time interval between the moment of call to the ambulance dispatch centre for an OHCA and the initiation of study compressions in the emergency department. For patients with an IHCA, this interval was the time interval between the call for cardiac arrest to the hospital switchboard and the first study compression.

For patients not surviving resuscitation, autopsy was requested to the family. In addition, we requested permission to perform a post-mortem high-resolution multislice computed tomography (CT) scan to be performed within 1-2 h after death.[@ehx318-B12] For patients initially surviving resuscitation, all data from the subsequent clinical course in the intensive care unit (ICU) were obtained.

Outcomes
--------

The primary outcome of the study was serious or life-threatening resuscitation-related damage to visceral organs, including large vessels and vertebrae as determined by post-mortem CT scan and/or autopsy or by clinical course (see [Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}). The secondary outcome was damage to bony structures of the chest wall (sternum and ribs). The study was analysed according to the actual treatment received, as acceptable for a safety study. The study was not intended nor powered to study survival for either of the two devices against manual controls, nor was the study intended to compare damage or survival between the two compression devices.

The post-mortem CT scans were evaluated by a panel of two experienced radiologists; autopsy was performed with a specific protocol. For patients surviving resuscitation, the subsequent clinical course until death or hospital discharge was evaluated for signs of visceral or chest cage damage by a panel of two radiologists, an intensivist and a cardiologist, using all available information. All assessors were blinded to the allocated treatment. During an autopsy, however, a characteristic round mark from the cup of the LUCAS or skin abrasions from the AutoPulse band could be visible and therefore the pathologist cannot be considered fully blinded.

The seriousness of the observed damage was distinguished in three levels of severity according to standard grading for patients in cardiac arrest[@ehx318-B13]:

\(i\) life-threatening---reasonably expected to interfere with cardiovascular or respiratory function, exsanguination in excess of 800 mL; (ii) serious---demands therapy for repair or for alleviation of pain, expected to prolong hospitalization; and (iii) insignificant---requires no therapy (expected to heal spontaneously without complication) or may require limited one-time only therapy. This definition of the primary endpoint was clinically oriented and could not be assessed in full if the patient did not survive the resuscitation attempt. In these cases, the panel classified the damage with the anticipation of a clinical course as if the patient had initially survived.

The secondary endpoint damage to the ribcage was defined as serious if it included sternal fractures and/or involved fractures to \>6 ribs if unilateral or \>4 ribs if at least one rib fracture was bilateral. Otherwise rib fractures were classified as insignificant. Damage to the ribcage and sternum was never considered life-threatening by itself.

For those patients who had a post-mortem CT scan as well as an autopsy, the most severe reported damage was used in the analysis.

Statistical analysis
--------------------

The study was designed as a non-inferiority study. The primary analysis tested whether mechanical chest compressions by either AutoPulse or LUCAS devices would not result in more life-threatening or serious visceral damage when compared with manual chest compressions. We assumed that the rate of serious or life-threatening visceral damage by manual chest compressions was 10%.[@ehx318-B13] To accept the non-inferiority hypothesis, the upper bound of the 95% confidence interval of an observed rate difference (RD) of damage between mechanical or manual chest compression-treated patients should not exceed +10%. To achieve a power of 80% and a one-sided *α* of 0.05, this required 2 × 112 patients in each comparison between experimental treatment and control.

Descriptive statistics were expressed as means with standard deviation or medians with interquartile range. Groups were compared with Student's *t*-test for continuous variables, the χ^2^ statistic for proportions or the Mann--Whitney *U* test for non-normally distributed continuous variables. Calculations were done with IBM SPSS Statistics for Mac V.20 (IBM, Armonk, NY, USA). Rate differences were calculated with their 95% confidence intervals according to Miettinen and Nurminen.[@ehx318-B14]

Results
=======

*Figure [1](#ehx318-F1){ref-type="fig"}* shows the randomization, exclusion and inclusion of the patients, and number of patients available for outcome assessment. The hospital resuscitation team was alerted for 1697 patients for whom a randomization envelope was opened. An AutoPulse was brought on scene for 574 patients, a LUCAS for 559 patients, and a Philips MRx for manual chest compressions for 564 patients. After exclusion criteria were assessed, an AutoPulse was used in 115 patients, a LUCAS device was used in 122 patients, while 137 patients received manual chest compressions. For details of the reasons for exclusion, see [Supplementary material online, *Table S2*](#sup1){ref-type="supplementary-material"}. Location of the arrest for IHCA patients is available in [Supplementary material online, *Table S3*](#sup1){ref-type="supplementary-material"}. Permission for autopsy and post-mortem CT scanning was denied by the family for 12 AutoPulse patients, for 14 LUCAS-treated patients, and for 11 control patients, who did not survive resuscitation. Possible damage could therefore be assessed by autopsy and/or post-mortem CT scan or by clinical follow-up in 103 AutoPulse patients, in 108 LUCAS-treated patients, and in 126 controls (for details of clinical diagnostic information, see [Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}). One surviving control patient refused consent, and her data were removed from analysis.

Baseline data are presented in *Table [1](#ehx318-T1){ref-type="table"}*. Age and gender were not significantly different between patients allocated to either mechanical chest compression devices or to manual control. For patients with OHCA, the interval between estimated initiation of manual chest compressions and connection of the study device was approximately 60 min, not significantly different between the experimental and control groups. For patients with IHCA, this interval was much shorter and significantly shorter for control patients. In the control group, the mean compression depth was slightly below the recommended 50 mm. The compression rate in the control group was within the recommended range.[@ehx318-B1]^,^[@ehx318-B2] For details of initial recorded rhythm and possible cause of arrest, see [Supplementary material online, *Tables S4*](#sup1){ref-type="supplementary-material"} and [*S5*](#sup1){ref-type="supplementary-material"}. Table 1Baseline and process dataAutoPulse (*n* = 115)LUCAS (*n* = 122)Manual control (*n* = 137)Gender male, *n* (%)75 (65.2)82 (67.2)87 (63.5)Age (years, mean ± SD)65 ± 1563 ± 1766 ± 13Location of arrest onset Out-of-hospital, *n* (%)53 (46.1)53 (43.4)50 (36.5) In-hospital, *n* (%)62 (53.9)69 (56.6)87 (63,5)Interval call-start study device (min, median, IQR)[^a^](#tblfn1){ref-type="table-fn"} Out-of-hospital60 (56--71)57 (48--62)57 (43--67) In-hospital10 (5--20)8 (4--11)5 (3--8)Duration of connection study device (min, median, IQR)21 (10--31)22 (7--39)16 (6--32)Compression depth (mm, mean ± SD)48 ± 9Compression rate (per minute, mean ± SD)110 ± 14[^2]

The primary outcome is presented in *Table [2](#ehx318-T2){ref-type="table"}*. Serious or life-threatening visceral resuscitation-related damage was seen in 12 of 103 AutoPulse patients (11.6%), in 8 of 108 LUCAS patients (7.4%), and in 8 of 126 controls (6.4%). The RD in occurrence of this primary endpoint between AutoPulse patients and control patients was +5.3% (95% CI −2.2% to 12.8%), *P* = 0.15 and between LUCAS patients and control patients +1.0% (95% CI −5.5% to 7.6%), *P* = 0.75 (*Figure [2](#ehx318-F2){ref-type="fig"}*). Table 2Primary and secondary outcomes in analysable patientsAutoPulse (*N* = 103)LUCAS (*N* = 108)Manual control (*N* = 126)Rate difference AutoPulse vs. control (%) (95% CI)^a^Rate Difference LUCAS vs. Control (%) (95% CI)^a^Resuscitation-related structural visceral damage (primary endpoint) Serious or life-threatening damage, overall, *n* (%)12 (11.7)8 (7.4)8 (6.3)5.3 (−2.2 to 12.8)1.0 (-5.5 to 7.6)  Out-of-hospital arrest onset, *n*/*N* (%)6/44 (13.6)3/46 (6.5)2/48 (4.2)9.4 (−2.1 to 21.1)2.4 (-6.7 to 11.5)  In-hospital arrest onset, *n*/*N* (%)6/59 (10.2)5/62 (8.1)6/78 (7.7)2.5 (−7.2 to 12.2)−0.23 (-8.9 to 8.4) Insignificant damage, *n* (%)6 (5.8)11 (10.2)13 (10.3) No damage, *n* (%)85 (82.5)89 (82.4)105 (83.3)Serious or life-threatening resuscitation-related visceral damage---details^b^ Pneumothorax, *n*624 Tension pneumothorax, *n*11--- Pneumomediastinum/oesophagus haematoma, *n*4------ Pleural fluid/blood, *n*133 Lung contusion/haematoma, *n*1---1 Liver rupture, *n*12--- Intracranial air embolism, *n*1------ Pneumoperitoneum, n---1---Resuscitation-related rib and sternum damage (secondary endpoint) Serious, *n* (%)47 (45.6)43 (39.8)52 (41.3)4.4 (−8.5 to 17.3)−1.5 (-14.1 to 11.2) Insignificant damage, *n* (%)10 (9.7)9 (8.3)22 (17.5) No damage, *n* (%)46 (44.7)56 (51.9)52 (41.3)Mean number of fractured ribs, mean ± SD[^c^](#tblfn4){ref-type="table-fn"}8 ± 48 ± 47 ± 4n.s.n.s.Sternum fractures, *n* (%)3 (2.9)7 (6.5)5 (4.0)−1.2 (−6.8 to 4.6)2.3 (-3.8 to 9.1)[^3][^4][^5]

![Rate differences of resuscitation-related serious or life-threatening damage between mechanical chest compressions and manual chest compressions. The dotted line at + 10% indicates the boundary of excess risk difference that should not be exceeded to accept the non-inferiority hypothesis.](ehx318f2){#ehx318-F2}

The secondary outcome (severe rib and/or sternum fractures) was observed in 47 of 103 AutoPulse patients (45.6%), in 43 of 108 LUCAS patients (39.8%), and in 52 of 126 controls (41.3%). The RD between AutoPulse and controls was +4.4% (95% CI −8.5 to 17.3), *P* = 0.51 and between LUCAS and controls −1.5 (95% CI −14.1 to 11.2), *P* = 0.82 (*Table [2](#ehx318-T2){ref-type="table"}*).

Death of three patients was clearly and directly attributable to the resuscitation damage itself: two patients with LUCAS compressions had a liver rupture with massive bleeding (one died during resuscitation and one died in the ICU) and one AutoPulse-treated patient had a tension pneumothorax with air embolism involving the brain and died during resuscitation. The great majority of patients died in the ICU from neurologic ischaemic damage or from their pre-existing disease (*Table [3](#ehx318-T3){ref-type="table"}*). Table 3In-hospital course after resuscitationAutoPulse (*N* = 115)LUCAS (*N* = 122)Manual control (*N* = 137)Did not survive resuscitation, *n* (%)72 (62.6)80 (65.6)69 (50.4)Admitted to ICU after resuscitation, *n* (%)43 (37.4)42 (34.4)68 (49.6)Mode of death in ICU Neurologic, *n*181126 Bleeding, *n*041 Sepsis, *n*114 Respiratory, *n*200 Pre-existing disease, *n*14714 Complication from resuscitation, *n*010 Unknown, *n*112[^6]

Discussion
==========

In this randomized clinical non-inferiority trial on resuscitation-related damage, we found that excess serious and life-threatening visceral damage did not exceed the pre-determined upper 95% confidence interval of 10% during LUCAS use and the non-inferiority hypothesis could be accepted. Significant excess damage from the use of the AutoPulse was not excluded because the upper 10% confidence interval of 10% excess damage was exceeded, and the non-inferiority hypothesis for the AutoPulse was not accepted.

The first randomized clinical trial with the AutoPulse, the ASPIRE trial, was published in 2006. That trial was stopped prematurely because of a trend of excess mortality with the use of the AutoPulse.[@ehx318-B7] Recently, three clinical trials on survival benefit from mechanical chest compression devices were published. The CIRC study did not show survival benefit of the AutoPulse over control with manual CPR.[@ehx318-B8] Two studies employing the LUCAS device, the LINC study and the PARAMEDIC study, showed no survival benefit to discharge from use of the device over manual control.[@ehx318-B10]^,^[@ehx318-B15] Nevertheless, these devices are used worldwide in large numbers. The Guidelines for Resuscitation from AHA and ERC 2015 consider mechanical chest compression acceptable for ongoing CPR during transportation or during coronary intervention.[@ehx318-B16]^,^[@ehx318-B17] These conditions for use of mechanical chest compression have not yet proved to benefit patients and make it even more important that we are certain that the devices do not harm.

Why did all randomized trials fail to demonstrate overall benefit? Interruption of chest compressions during device positioning[@ehx318-B18]^,^[@ehx318-B19], shifting device position during use to vulnerable places on the chest or abdomen, or too forceful compressions could be an explanation. Studies of potential damage from mechanical chest compression devices have been published and a variety of damage is reported, mostly from autopsy reports.[@ehx318-B20] The absolute difference in observed visceral damage between these studies is striking: in the study of Smekal *et al.*,[@ehx318-B20] visceral damage was observed in 28% and 19% in LUCAS-treated and manual-treated patients, respectively, with an odds ratio of 1.6 (95% CI 0.84--3.2). In the study of Lardi *et al.*,[@ehx318-B22] visceral damage in LUCAS-treated and manual-treated patients was 19% and 25%, respectively, with an odds ratio of 0.76 (95% CI 0.22--2.6), but in Pinto *et al.*'s[@ehx318-B21] study, this was only 3% and 1%, respectively, with an odds ratio of 3 (95% CI 0.3--30). A recent large retrospective cohort study using post-mortem CT scans compared AutoPulse treatment with controls.[@ehx318-B23] The odds ratio of abdominal injury in AutoPulse treated patients was 4.9 (95% CI 1.88--12.9). In all patients, both mechanical and manual chest compressions were given. Being a non-randomized study, the contribution of mechanical chest compression to damage cannot be clearly established. Our randomized study with damage assessment in \>90% of all included patients allows a better assessment of the possible contribution of mechanical devices to damage from chest compressions, as the duration of initial manual CPR prior to device application was similar in all groups.

The numbers of various kinds of damage are too small to draw conclusions on their cause. The LUCAS concentrates its force on the sternum, and this may explain why more sternum fractures were observed in patients treated with LUCAS. The AutoPulse may generate high intra-thoracic pressure because of the force on the circumference of the chest. Severe rib and sternum damage did not occur significantly more in both mechanical chest compression devices. Rib and sternum damage was not considered life-threatening in itself, but it may have caused severe or life-threatening visceral pulmonary or mediastinal damage such as tension pneumothorax, mediastinal bleeding, or mediastinal emphysema.

Damage classified as life-threatening does not imply that it actually had caused death. In the setting of a cardiac arrest, the cause of the arrest, its consequences (e.g. aspiration or cerebral ischaemia), and the complications of chest compressions (e.g. pleural bleeding or pneumothorax) are a mix of conditions that each could contribute to death after resuscitation. In only three patients, the visceral damage could be classified as lethal in itself: liver rupture with massive bleeding and tension pneumothorax with cerebral air embolism.

Autopsy is not routinely performed after failed resuscitation, and most studies that report resuscitation-related damage only rely on autopsy performed in a minority of non-survivors. In a study specifically aimed to investigate damage from mechanical chest compressions, 222 of 691 non-surviving patients (32%) of a subset of the LINC study had an autopsy and patients with mechanical chest compressions were over-represented in the sample.[@ehx318-B20] In the study of Pinto *et al.*,[@ehx318-B21] it was unclear from what population of cardiac arrest the autopsy patients were originating. In our study, autopsy was permitted in only 70 of the 221 patients (32%) who did not survive the resuscitation. Because we added post-mortem CT scanning to our protocol, we could assess damage outcome in 90% of all patients in the study. Post-mortem CT scanning has initially been used in forensic medicine but also has been investigated for assessment after resuscitation. In general, there is a reasonable agreement between postmortem CT and autopsy. In some studies, rib and sternum damage was found more frequent in CT scans, but some visceral damage identified more often in autopsy.[@ehx318-B12]^,^[@ehx318-B24]^,^[@ehx318-B25] More control patients survived resuscitation (50%) than AutoPulse (37%) or LUCAS patients (34%) and therefore more often clinical diagnostic information was available (see [Supplementary material online, *Table S1*](#sup1){ref-type="supplementary-material"}). Many patients in the ICU had CT scans driven by suspicion of damage from chest compressions. We believe therefore that diagnostic bias was not relevant for this reason.

In our study, randomization took place before inclusion criteria and exclusion criteria could be assessed. This may raise concern of bias in treatment allocation. There was no significant difference in allocation to treatment groups, except for the exclusion criterium ROSC on arrival of the resuscitation team (*Table [1](#ehx318-T1){ref-type="table"}*). This can be explained by the fact that preparing and applying a mechanical chest compression device took on average 3--5 min longer than applying a sternal displacement transducer in the control group, a significant difference. Therefore, there was 3--5 min more time for ROSC to occur before the mechanical compression device was in place, while for those patients allocated to manual control, chest compressions had started earlier, before ROSC may have occurred. There was a notably higher number of device failures of the Autopulse caused by battery failure, resulting in some inbalance in active treatment. This did not affect the interpretation of the outcome of interest (damage) in patients who received active treatment.

There is an association between longer duration of CPR and more bone and visceral damage.[@ehx318-B26] Approximately half of the patients had the onset of cardiac arrest outside the hospital and had manual chest compressions during transport for refractory cardiac arrest before the study device was applied after hospital arrival. The duration of chest compressions before inclusion in the study was evenly distributed between mechanical and manual chest compression in the OHCA patients, the rate of severe damage even tended to be higher in the IHCA patients. Therefore, it is unlikely that the prolonged period of chest compressions in the OHCA patients confounded the comparison of damage rates in patients receiving mechanical or manual control chest compressions, but a specific contribution to possible severe or life-threatening damage during transportation was not assessed in this study. In the Resuscitation Guidelines of 2015 ambulance transport to the hospital with mechanical chest compression is reasonable for emergency coronary angiography of patients who failed to have return of organized rhythm before transport.[@ehx318-B16]^,^[@ehx318-B17] In that context, longer duration of mechanical chest compression can be expected than studied in our patients.

Conclusions
===========

The use of mechanical chest compressions with the LUCAS device does not cause more severe or life-threatening visceral damage than good quality manual chest compressions. For mechanical chest compressions with the AutoPulse, it cannot be excluded that more severe or life-threatening damage is caused, compared with good quality manual chest compressions.
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[Supplementary material](#sup1){ref-type="supplementary-material"} is available at *European Heart Journal* online.
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[^2]: For out-of-hospital cardiac arrest, the call was the call to the dispatch centre; for in-hospital cardiac arrest, it was the call to the hospital central switchboard.

[^3]: 95% confidence interval according to Miettinen.[@ehx318-B14]

[^4]: Some patients had more than one kind of serious or life-threatening visceral damage.

[^5]: Calculated for the patients with rib fractures.

[^6]: ICU, intensive care unit.
